Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT00040859
- Locations
- 🇺🇸
Mercy Medical Center - Sioux City, Sioux City, Iowa, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Oxaliplatin in Treating Patients With Liver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00052364
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00006465
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 43
- Registration Number
- NCT00047177
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00025337
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00003799
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019773
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Mount Hospital, Perth, Western Australia, Australia
🇦🇺Frankston Hospital, Frankston, Victoria, Australia
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00051688
- Locations
- 🇺🇸
Cancer Institute Medical Group, Santa Monica, California, United States
🇺🇸ACRC/Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00006062
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.